|Bid||0.00 x 3200|
|Ask||0.00 x 1100|
|Day's range||55.99 - 56.91|
|52-week range||52.65 - 71.70|
|Beta (5Y monthly)||0.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1.45 (2.64%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
WILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
WILMINGTON, Del., September 16, 2022--A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) showed positive high-level results in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).
WILMINGTON, Del., September 15, 2022--Today, AstraZeneca (Nasdaq: AZN) launched Up The Antibodies, an important new campaign that embraces the reality for millions of immunocompromised Americans1,2: COVID-19 isn’t over. While it feels like life has gone back to normal for many, this community still has very real cause for concern. Now, an added layer of COVID-19 protection can help people who are immunocompromised start to get back out into the world, doing what they love with whom they love.